Catalyst Event
Astrazeneca PLC (AZN) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
6/2/2026, 12:00:00 AM
Presented positive final results from the Phase III SERENA-6 trial for camizestrant in breast cancer at the ASCO 2026 Annual Meeting, showing a 37% reduction in risk of second disease progression or death. High importance estimated due to significant clinical success in a major indication.
Korean Translation
ASCO 2026 연례회의에서 유방암 치료제 카미제스트란트(camizestrant)의 SERENA-6 3상 임상시험 최종 긍정적 결과를 발표했으며, 2차 질병 진행 또는 사망 위험을 37% 감소시킨 것으로 나타남. 주요 적응증에서의 유의미한 임상적 성공으로 인해 높은 중요도로 평가함.
Related Recent Events
Alphabet Inc (GOOGL) · Earnings Release
Alphabet Q2 2026 earnings release scheduled for July 22, 2026, with analysts forecasting EPS of approximately $2.85-$2.87 forecasted.
7/22/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Other
Alphabet held its 2026 Annual Meeting of Shareholders on June 5, 2026. Proposals included an increase to the 2021 Stock Plan share reserve.
6/5/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Other
Hims & Hers appointed Dr. Anant Vinjamoori as its new Chief Medical Officer on 2026-06-04, which resulted in a 7.23% stock price increase.
6/4/2026, 12:00:00 AM
Natera Inc (NTRA) · Other
Announced a strategic collaboration with CytoDyn to use its ctDNA platform to support CytoDyn's metastatic colorectal cancer development program.
6/4/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Announced on 2026-06-03 plans to halve its €2.3 billion investment in a new German plant; medium impact estimated due to regulatory headwinds and reduced growth capacity, expected.
6/3/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Other
The UK's Competition & Markets Authority (CMA) announced on June 3, 2026, new conduct requirements for Google's AI-powered search, giving publishers more control over their content.
6/3/2026, 12:00:00 AM